Skip to content
primarysourced Photonics sector Tower
TSEM
~17 min read · 3,893 words ·updated 2026-04-29 · confidence 21%

Confidence legend: ✓ verified-primary (SEC EDGAR filing, Federal Register, Israel ISA filings, Tower 20-F / 6-K, Israeli Companies Law text) · ◐ partial / aggregator · ⚠ inferred / estimate / backfill needed.

This page maps the regulatory-and-public-policy landscape that materially shapes Tower Semiconductor’s financial structure, capacity-expansion economics, and disclosure regime. Six regimes matter: (1) Israeli Companies Law 1999 — the corporate-governance foundation; (2) Israel Securities Authority (ISA) regime — Tower is an Israeli-incorporated company subject to ISA oversight; currently NASDAQ-only (TSEM) per EDGAR submissions feed verified 2026-04-29; the historical TASE secondary listing under TSEM.TA appears to have been delisted (exact date pending primary-source verification); (3) US Foreign Private Issuer regime — 20-F annual + 6-K interim cadence; (4) HFIAA (effective 2026-03-18) — ends FPI Section 16(a) carve-out for officers, directors, and 10%+ holders; (5) China antitrust (SAMR) — the regulatory force that killed the Intel-Tower deal; (6) US CHIPS Act + Israel innovation grants — funding programs and Tower’s status under each.

1. Israeli Companies Law 1999

Foundation framework

Tower Semiconductor Ltd. is an Israeli public company organized under the Israeli Companies Law of 1999 (“the Companies Law”). The Companies Law governs:

  • Board of directors composition + duties
  • Shareholder rights + voting procedures
  • Related-party transaction rules
  • Officer compensation approval requirements (Compensation Policy)
  • Public-company specific disclosure obligations

Key Companies Law features relevant to Tower investors:

  • Mandatory External Directors (Dachatz) — Israeli public companies must have at least two external directors satisfying specific independence criteria. Approval and re-election cycles differ from standard US-style independent directors.
  • Compensation Policy approval — executive compensation policy must be approved by shareholders at general meetings; the policy itself is multi-year and re-approved every 3-5 years.
  • Special-tender-offer rules — shareholder approval thresholds for tender offers differ from US standards; relevant to any future strategic-acquirer scenario.
  • Class-action / derivative-suit rules — Israeli courts allow derivative actions and class actions against public companies under specific conditions.

✓ The Companies Law text is publicly available (Hebrew-original; English translations published by Israeli Ministry of Justice and various law firms). For Tower-investor purposes, the relevant provisions are summarized in the Tower 20-F Item 6 (Directors, Senior Management, and Employees) + Item 10 (Additional Information). ⚠ Specific 20-F section extractions backfilled in governance.

Implications for Tower investors

  • Different shareholder voting mechanics vs Delaware-incorporated US companies — tender-offer thresholds, class-vote requirements, etc.
  • Mandatory external-director independence test ensures Tower has independent oversight, but with Israeli-specific criteria.
  • Compensation Policy is shareholder-approved — provides material visibility into executive incentive structure.
  • Related-party transaction disclosure — multiple-tier approval requirements for transactions involving controlling shareholders, officers, or directors.

⚠ Tower has historically NOT had a single controlling shareholder (post-2014 Bank Leumi shareholding wind-down). The Israel Corp + Israeli institutional investors are the largest holders but no single shareholder approaches a controlling block. This is materially different from companies with controlling-shareholder structures (e.g., Mubadala-controlled GFS).

2. Israel Securities Authority (ISA) — current regime + historical dual-listing

Current state — NASDAQ-only

Per SEC EDGAR submissions feed (exchanges field) verified 2026-04-29, Tower Semiconductor currently trades on NASDAQ Global Select Market (ticker: TSEM) only. The TASE secondary listing under TSEM.TA that existed historically appears to have been delisted; exact delisting date is ⚠ pending primary-source verification (Tower 6-K announcing TASE delisting, or ISA-side disclosure).

Historical dual-listing regime — context (now-historical)

Tower previously qualified under Israel’s dual-listing regulation as an Israeli company primarily listed on NASDAQ AND traded on TASE. That regime granted regulatory accommodations that reduced the dual-disclosure burden:

  • No requirement to file separate Hebrew-language financial statements under ISA rules; Tower could file its US-GAAP-prepared financial statements as the basis for both NASDAQ and TASE.
  • No requirement to comply with separate ISA-specific corporate governance rules beyond Companies Law requirements; Tower’s NASDAQ-listing-rules compliance was treated as sufficient.
  • Disclosure cadence aligned with US 20-F / 6-K cadence rather than ISA-specific quarterly filing requirements.

✓ The dual-listing regime was governed by the Israeli Securities Law (Article XX or similar; specific section number ⚠ backfill from primary source) and ISA’s published guidance on the “Foreign Issuer track.” This framework is now of historical interest only for TSEM specifically — relevant to other Israeli FPIs that maintain dual listings.

Practical implications today

  • Tower’s primary-source disclosures are filed as Form 20-F (annual) + Form 6-K (interim) on SEC EDGAR.
  • Hebrew-language insider-disclosure portal (Maya / ISA) historically also published Tower-affiliated reports; pre-HFIAA insider-transaction history that does NOT appear in EDGAR Form 4 may exist there. ⚠ Maya portal ingestion remains a documented backfill task — not a near-term action item.
  • Tower investors should monitor SEC EDGAR (Tower CIK 0000928876) as the primary filing source.

3. US Foreign Private Issuer (FPI) Regime

FPI status

Tower Semiconductor qualifies as a Foreign Private Issuer (FPI) under SEC rules:

  • Israeli-incorporated company.
  • Most directors and officers are non-US citizens.
  • Most operations are conducted outside the US (despite Newport Beach + San Antonio fabs).
  • Listed on NASDAQ but maintains Israeli HQ.

FPI accommodations

As an FPI, Tower benefits from:

  • Form 20-F annual report instead of Form 10-K (longer filing window, more flexibility on content).
  • Form 6-K interim filings instead of Form 10-Q (no specific cadence requirement; filed when material events occur or to convey foreign-jurisdiction-required disclosures).
  • No proxy statement (DEF 14A) requirement for shareholder meetings.
  • No quarterly XBRL detailed-tagging requirement at the level of US-domestic issuers.
  • Pre-HFIAA (pre-2026-03-18): officers + directors + 10%+ holders were exempt from Section 16(a) Form 3 / Form 4 / Form 5 reporting.
  • IFRS or US GAAP optionality — Tower files in US GAAP (a reflection of its NASDAQ-primary listing and US investor base).

Disclosure cadence

Tower’s standard disclosure cadence:

  • Form 20-F filed annually within 4 months of fiscal year-end (typically March-April; FY 2024 20-F filed 2025-04-30).
  • Form 6-K filed for material events: quarterly earnings releases, major design-win announcements, board changes, capital markets transactions, geopolitical-risk disclosures.

Per the Tower FY 2024 20-F filing (acc. 0001178913-25-001537) ✓, Tower’s 20-F is comprehensive (Items 1-19 covering business overview, risk factors, financials, governance, etc.).

4. HFIAA — End of FPI Section 16(a) Carve-Out (2026-03-18)

What HFIAA does

The Holding Foreign Insiders Accountable Act (HFIAA), signed 2025-12-18 and effective 2026-03-18, ends the Section 16(a) carve-out for FPI officers, directors, and 10%+ beneficial owners. ✓ Harvard CorpGov — Section 16(a) Insider Reporting Legislation Ends FPI Exemption (2026-01-18)

Why it matters for Tower

Pre-2026-03-18:

  • Tower officers + directors + 10%+ holders were NOT required to file Form 4 (transactional) reports.
  • Tower insider-trading patterns were NOT publicly observable in real-time.
  • Insider stock activity was visible only via 20-F / 6-K aggregate disclosures (with significant lag).

Post-2026-03-18:

  • Tower officers + directors + 10%+ holders ARE required to file Form 3 (initial), Form 4 (changes), and Form 5 (annual) reports.
  • Form 4 must be filed within 2 business days of any beneficial-ownership change.
  • This provides real-time analyst-grade visibility into insider-trading patterns at Tower for the first time.

Compliance timeline

  • Form 3 (initial): due 2026-06-16 (90 days from 2026-03-18) for all current officers, directors, and 10%+ holders.
  • Form 4 (changes): within 2 business days of any beneficial-ownership change after 2026-03-18.
  • Form 5 (annual): within 45 days of fiscal year-end (first deadline 2026-02-15 for FY 2025 events occurring post-effective-date).

Specific Tower implications

  • Russell Ellwanger (CEO), Oren Shirazi (CFO), Eran Briman (COO), Yaron Eisenstein (CRO), Jay Abrams (General Counsel), Dani Tomer (CTO) ⚠ — confirm exact officer roster from latest 20-F — all subject to Section 16(a) reporting post-2026-03-18.
  • Board members subject to reporting include Russell Ellwanger (Executive Chairman), Amir Elstein (Chairman), and other directors per latest 20-F. ⚠
  • Israel Corp historically holds a meaningful Tower position. ⚠ Confirm whether Israel Corp’s holding crosses the 10% threshold post any recent share-buyback or institutional flow shifts.
  • The Daily-refresh-pipeline that this research site uses for LWLG (always-domestic) Form 4 filings now applies to TSEM as well, post-2026-03-18.

⚠ As of 2026-04-29 (this filing date), the first wave of Tower Form 3 filings has presumably been made or is in progress; the May-June 2026 timeframe will reveal the full slate of Tower insider reporting. Backfill specific Form 3 / Form 4 filings as they appear on SEC EDGAR. The Daily refresh-cadence pipeline should track SEC EDGAR — TSEM full-text search ✓ for new filings.

5. China Antitrust (SAMR) — The Intel-Deal-Killer

Background

China’s State Administration for Market Regulation (SAMR) is the antitrust regulator with jurisdiction over mergers involving Chinese-revenue-threshold-meeting parties. The semiconductor industry’s worldwide-revenue scale means most large foundry mergers require SAMR clearance.

The Intel-Tower deal context

The proposed Intel-Tower merger (announced 2022-02-15; terminated 2023-08-16) provides the canonical case study of SAMR’s role as a regulatory blocker for cross-Pacific specialty-foundry consolidation:

  • 2022-Q3: Intel + Tower file with SAMR for clearance.
  • 2022-Q3 to 2023-H1: Multiple amendments to the merger agreement to extend the outside date past the original 1-year window, allowing more time for SAMR review.
  • 2023-08-15: Outside date passed without SAMR clearance.
  • 2023-08-16: Intel + Tower jointly terminated the merger; Intel paid Tower a $353M reverse-termination fee.

China SAMR did NOT formally reject the deal — it simply did not act on it within the agreed-upon outside date. ✓ Per Intel 8-K filed 2023-08-16 and Tower 6-K of same date. See Intel deal collapse for the full memo.

The strategic-positioning implications

  • Cross-Pacific specialty-foundry M&A is structurally constrained. The same logic that killed Intel-Tower would likely apply to a hypothetical TSMC-Tower, GFS-Tower, or Samsung-Tower combination.
  • Tower’s standalone status is durable — not transient. This reflects geopolitical reality, not corporate strategy.
  • Any future strategic transaction involving Tower would need to navigate SAMR carefully — likely requiring meaningful Chinese-side concessions or structural re-design (e.g., divestiture of Chinese-customer wafer flows).

⚠ The post-Intel-deal observable: no major strategic-acquirer has emerged for Tower as of 2026-04-29, consistent with the SAMR-induced structural constraint.

Forward SAMR risk for Tower’s existing operations

  • Tower has Chinese fabless customers; this customer mix is ongoing.
  • Tower’s 2024-2025 capacity expansion (CPO Foundry, 300mm SiPh, Agrate 300mm BCD ramp) does not require SAMR review (capacity expansion, not M&A).
  • Future Tower M&A or strategic-transaction structures would face SAMR scrutiny similar to the Intel deal.

6. US CHIPS Act — Tower Exposure (LIKELY NO DIRECT AWARD AS OF 2026-04-29)

Tower’s CHIPS Act status

⚠ As of 2026-04-29 per public record, Tower has NOT received a direct CHIPS Act award. This is materially different from:

Tower has US-based fab capacity:

  • Newport Beach Fab 3 (200mm; legacy Jazz Semiconductor; from 2008 Tower-Jazz merger).
  • San Antonio Fab 9 (acquired 2016 from Maxim).
  • Intel Fab 11X capacity-services arrangement (Rio Rancho, NM; $300M; announced Sep 2023; Tower processes wafers using Intel’s Fab 11X tools — NOT a Tower-owned facility).

The Tower-Intel Fab 11X arrangement is NOT a CHIPS-Act-funded Tower facility — it is a capacity-services contract with Intel, which itself received separate CHIPS Act funding for its Rio Rancho operation. The CHIPS Act flow at Rio Rancho goes to Intel, not to Tower.

Why no direct Tower CHIPS Act award

⚠ Possible reasons (analyst-class inference):

  • Tower’s US fab footprint is smaller than the multi-billion-dollar greenfield expansion programs prioritized in the CHIPS Act Direct Funding tier.
  • Tower’s existing US capacity (Newport Beach + San Antonio) is operating under capacity arrangements that don’t directly require federal grant support.
  • Tower’s primary capacity-expansion focus is the Tower-ST Agrate 300mm program (Italy) and SiPh expansion (US + Israel) — neither qualifies for US CHIPS Act direct funding at the scale of the major awards.
  • Tower may have applied for or be eligible for CHIPS Act tax-credit (Section 48D Investment Tax Credit at 25% of qualified-property-cost) without the Direct Funding tier.

⚠ Open audit item: Confirm in Tower’s FY 2024 20-F MD&A and risk-factors whether Tower has applied for or received any CHIPS Act tax credits (Section 48D), or whether Tower has applied for and been declined Direct Funding tier awards.

⚠ Open audit item: Confirm whether Tower’s role at Intel Fab 11X qualifies for any CHIPS Act flow-through (e.g., as part of Intel’s awarded program scope).

CHIPS Act Section 48D Investment Tax Credit

The CHIPS Act includes a 25% federal tax credit on qualifying semiconductor manufacturing property under Section 48D. Tower may potentially benefit from Section 48D for Newport Beach + San Antonio capex if Tower’s qualifying property meets the tax-credit criteria. ⚠ This would be disclosed as a deferred-income / tax-credit benefit in the 20-F notes to financial statements; backfill from primary source.

7. Israel Innovation Authority + BIRD Foundation Grants

Israel Innovation Authority

The Israel Innovation Authority (IIA, formerly the Office of the Chief Scientist) is the Israeli government agency that administers R&D grants, technology-incubator programs, and strategic-technology subsidies. Tower has historically benefited from IIA grants supporting:

  • Process development for advanced specialty-foundry nodes.
  • Pilot-line / prototype development.
  • R&D partnerships with academic institutions (Technion, Weizmann, etc.).

The grants are typically structured as forgivable / royalty-bearing — Tower repays the grant via royalties on commercial revenue derived from the funded R&D, capped at the grant amount + interest. This shows up in Tower’s 20-F notes to financial statements as deferred-income / royalty-payable line items.

⚠ Specific IIA grant amounts and royalty obligations are disclosed in Tower’s 20-F notes; backfill from latest 20-F.

BIRD Foundation

The Binational Industrial Research and Development (BIRD) Foundation funds joint US-Israel industrial R&D projects. Tower has historically participated in BIRD-funded projects with US partners. The BIRD-Energy program specifically funds joint US-Israel cleantech R&D — whether Tower has BIRD-Energy participation is ⚠ unclear from public record; backfill in next refresh.

Implications

  • IIA + BIRD grants reduce Tower’s net-cash R&D burden but introduce future royalty-payable obligations.
  • For an analyst, these are lower-impact regulatory items vs CHIPS Act / SAMR / HFIAA — but provide capital-cost reduction at the margin.
  • The grants also serve as Israeli-government endorsement of Tower’s strategic-technology portfolio.

⚠ Backfill specific grant amounts + royalty-obligations from Tower 20-F notes in next refresh.

8. Israel Geopolitical Conflict — 2023-2024 Disclosure Considerations

Background

The Israel-Hamas conflict that began 2023-10-07 materially affected Israeli companies’ operational disclosures and risk-factor frameworks. The conflict has continued at varying intensity through 2024-2026 with:

  • Ground operations in Gaza (Oct 2023 - present).
  • Lebanon / Hezbollah front (escalating in 2024).
  • Iranian / Houthi tail risks.
  • Israeli reservist call-ups affecting workforce availability.

Tower-specific operational implications

⚠ Tower 6-K disclosures in Q4 2023, Q1 2024, Q2 2024 should contain operational-impact language related to the conflict. Specific items expected to appear in the 6-K filings:

  • Migdal Haemek Fab 1 + Fab 2 operational continuity — both Tower’s primary Israeli fabs are in northern Israel; reservist call-ups affecting workforce availability would be disclosed.
  • Israeli employees on reserve duty — quantification of workforce-attendance impact.
  • Logistics / supply chain disruption — air freight, port operations, customer-shipment delays.
  • Insurance / risk-management responses — incremental insurance costs, Israeli government insurance backstops.
  • Customer-side concerns — whether any customers paused or reduced wafer-starts due to Israel-conflict concerns.

⚠ Specific quotation language for Tower’s Israel-conflict-period 6-K disclosures has NOT been directly extracted in this research pass. This is a flagged backfill item. The relevant 6-K filings to extract are:

  • Q3 2023 6-K (filed Oct/Nov 2023) — first post-conflict filing.
  • Q4 2023 6-K (filed Feb 2024) — Q4 2023 results + risk-factor update.
  • Q1 2024 6-K (filed May 2024) — Q1 2024 results + ongoing-conflict commentary.
  • Q2 2024 6-K (filed Aug 2024) — Q2 2024 results.
  • FY 2023 20-F (filed April 2024) — annual risk-factor disclosure.
  • FY 2024 20-F (filed April 2025) — most recent annual risk-factor disclosure ✓ SEC EDGAR.

⚠ TODO: Direct quotation extraction of Israel-conflict language from these specific filings to substantiate the risk-factor-disclosure framing for the Tower thesis.

Why this matters for Tower analysts

The Israel-conflict risk is a multi-year geopolitical-risk overlay on Tower’s standalone equity story. Analyst-grade theses must:

  • Quantify the operational impact (workforce attendance, delivery delays, costs).
  • Distinguish between transient conflict-period disruptions and structural Israeli-operations concerns.
  • Track Tower management’s specific disclosure language across the multiple 6-K filings.
  • Cross-reference Tower’s geographic diversification (US fabs + Italy JV + Japan TPSCo) as the operational-resilience hedge against Israeli concentration.

The Israeli geopolitical-risk framing is a dual-edged factor:

  • Negative: continued conflict + reservist call-ups + workforce-attendance impact + Houthi shipping risk + Iranian tail risk.
  • Positive: Tower’s Israeli capacity is strategically isolated from US-China decoupling pressures; Israeli foundry capacity has a unique geopolitical signature that some customers value precisely BECAUSE it’s neither US-CHIPS-anchored nor Chinese-domestic.

9. BIS Export Controls

Tower’s exposure

The US Bureau of Industry and Security (BIS) has progressively tightened export controls on advanced-semiconductor technology destined for China since October 2022. The regime includes:

  • Section 1758a Advanced Computing controls (≥4.5 TOPs at FP16 or similar).
  • Foreign Direct Product Rule (FDPR) extensions.
  • Entity List restrictions.

Tower’s specialty-foundry processes (PH18 SiPh, SiGe BiCMOS, BCD, CIS, MEMS) are typically AT OR ABOVE the technology nodes covered by advanced-computing restrictions. Tower does NOT produce advanced GPUs, advanced HBM, or A14-class accelerators. The bulk of Tower production volume is therefore NOT subject to advanced-computing export controls.

Where Tower has BIS exposure

  • Tower customers that ARE subject to BIS controls — if Tower fabs wafers for a customer whose end product is restricted, the wafer-level transaction may carry compliance burden.
  • End-application-specific controls — automotive radar, advanced RF, certain photonic / optical applications can be subject to specific export-control rules.
  • Defense / dual-use applications — the Tower-Axiro defense-applications announcement (2026-04-27) ✓ implicates ITAR / EAR compliance; Tower’s US-based fab capacity is a positive factor for compliance ease.

⚠ The 20-F Item 3.D risk-factor section discusses export-control exposure in detail; backfill specific language in next refresh.

Israel-side export controls

Israel has its own export-control regime governed by the Israeli Ministry of Defense (Defense Export Controls Agency) and Ministry of Economy. Some Tower products may be subject to Israeli defense / dual-use export controls in addition to US BIS controls. ⚠ Backfill from Tower 20-F.

10. Cayman / Israel / US Tax Structure

Israel-incorporated parent

Tower Semiconductor Ltd. is Israeli-incorporated, subject to Israeli corporate tax. Israel’s standard corporate tax rate is 23%, but Tower benefits from various Approved Enterprise / Beneficiary Enterprise programs that provide reduced effective tax rates on qualifying revenue.

US operating subsidiaries

  • Jazz Semiconductor / Tower US (Newport Beach + San Antonio) — subject to US federal corporate tax (21% statutory) plus state corporate taxes (CA, TX).
  • CHIPS Act tax credits (Section 48D 25% Investment Tax Credit) — potentially applicable to qualifying property; ⚠ confirm in 20-F.

Italian operations (Agrate JV)

  • Tower-ST Agrate JV — capacity arrangement with STMicroelectronics; revenue accounting treated as service-fee allocation. ⚠ confirm specific accounting structure in 20-F.

Japanese operations (TPSCo)

  • TPSCo Japan — Tower owns a 51% stake; remaining 49% held by Nuvoton (the JV partner). Subject to Japanese corporate tax.

Effective tax rate

⚠ Tower’s effective tax rate has historically ranged from low single-digit % to mid-teens %, reflecting:

  • Israeli Approved-Enterprise tax incentives.
  • Use of Israeli NOLs from earlier loss-period operations.
  • Geographic mix of revenue / income across Israel + US + Italy + Japan.

Pillar Two / Global Minimum Tax (15% effective rate floor on multinationals) entered into force in EU member states starting 2024 and is being implemented globally. Tower would be subject to top-up tax for any jurisdiction where the effective tax rate falls below 15%. ⚠ Specific top-up tax exposure varies by year and jurisdiction; confirm in 20-F Item 5.

11. Reading the Regulatory Signals for Tower

For an analyst tracking Tower’s regulatory landscape, the highest-value signals to monitor:

  • Tower 20-F annual filing (filed each April) — full risk-factor disclosure including Israel-conflict-period language, BIS export-control exposure, CHIPS Act status.
  • Tower 6-K filings — interim disclosures of geopolitical-impact updates, design-win announcements, M&A activity.
  • Tower Form 3 / Form 4 / Form 5 filings (post-2026-03-18) — first-time-real-time visibility into insider-trading patterns.
  • SEC EDGAR full-text search for “Tower Semiconductor” — comprehensive filing tracker.
  • Federal Register CHIPS Act announcements — any future direct or indirect Tower CHIPS funding flow.
  • SAMR antitrust commentary — any signal of relaxation in Chinese-antitrust posture toward US-Israel semiconductor M&A.
  • Israel ISA filings (TASE secondary filings) — typically echoes SEC filings but can occasionally include Israel-specific disclosure timing.
  • Israel Innovation Authority press releases — new grant programs that Tower may participate in.
  • HFIAA enforcement enforcement actions / SEC guidance — clarification of FPI Section 16(a) implementation as the regime matures through 2026-2027.

The single most important regulatory monitoring task: track Tower Form 3 + initial Form 4 filings post-2026-03-18 to establish the baseline insider-ownership map and post-effective-date transactional patterns. Pre-HFIAA, this was not possible.

12. Open Items / Backfill Queue

  1. ⚠ Israel geopolitical-conflict 6-K specific quotation language — 2023-Q4, 2024-Q1, 2024-Q2 6-K filings need direct extraction of operational-impact and risk-factor language. THIS IS THE SINGLE-LARGEST FACTUAL GAP IN THIS PAGE.
  2. ⚠ Tower CHIPS Act Section 48D tax-credit application status — confirm in FY 2024 20-F notes; not directly extracted in this research pass.
  3. ⚠ Tower CHIPS Act Direct Funding application status — confirm whether Tower applied for and was declined any awards.
  4. ⚠ Israel Innovation Authority specific grant amounts + royalty obligations — backfill from 20-F notes to financial statements.
  5. ⚠ BIRD Foundation participation by Tower — unclear from public record; backfill.
  6. ⚠ Tower Form 3 filings post-2026-03-18 — extract once filed (deadline 2026-06-16).
  7. ⚠ Israel Corp + Israeli institutional investor 10%+ thresholds — confirm whether any Tower shareholder crosses the 10%+ threshold for HFIAA Section 16(a) reporting.
  8. ⚠ Israeli Approved Enterprise / Beneficiary Enterprise specific tax-rate detail — backfill from 20-F.
  9. ⚠ BIS Israel-side export controls — Tower may have Israeli defense / dual-use control obligations beyond US BIS; backfill.
  10. ⚠ 20-F Item 3.D risk-factor language extractions — comprehensive risk-factor coverage backfill in next refresh pass.

Cross-section pointers

  • foundry industry dynamics — Specialty-foundry market structure context.
  • AI capex cycle — Hyperscaler-capex demand that Tower’s specialty franchise captures.
  • silicon photonics market — SiPh-segment competitive dynamics that depend on regulatory geographies (Tower Israel + US vs GFS US + Singapore + Germany).
  • TAM / SAM — Bottom-up addressable-market sizing; regulatory factors constrain SAM (e.g., BIS export controls on Chinese-end-customer revenue).
  • Intel deal collapse — The canonical SAMR-driven termination case study.
  • leadership — Officer + director roster subject to HFIAA Section 16(a) reporting.
  • timeline — Regulatory milestones in Tower’s history.
  • LWLG regulatory landscape — Cross-reference for the customer-side regulatory analysis (LWLG modulator-IP customers face the same BIS / EAR exposure).
  • GFS regulatory landscape — Cross-reference for the competitor’s regulatory analysis ($1.5B CHIPS Act award provides direct comparison to Tower’s no-direct-award status).